Resumen

CRISOL-DEZA, Diego André; ZURITA-BORJA, Joselyn Linda  y  CRISOL-DEZA, Yetsli Geraldine. Development of rheumatoid arthritis refractory to conventional treatment. Rev Cuba Reumatol [online]. 2021, vol.23, n.3  Epub 01-Abr-2022. ISSN 1817-5996.

Rheumatoid arthritis is a systemic chronic inflammatory disease that affects 0.4% to 1% of Latin America, manifested by chronic pain, joint destruction and premature death, affecting mainly women. Using the Health Assessment Questionnaire score, a count of swollen joints, presence of rheumatoid nodules, rheumatoid factor, erythrocyte sedimentation rate, C-reactive protein and erosions in radiography, were associated with the choice of the first treatment with disease-modifying antirheumatic drugs (DMARDs). To determine the main studies that ensure efficacy towards the development of rheumatoid arthritis refractory to conventional treatment. The literature search was carried out by means of an exploration of articles in PubMed and SciELO; Original and review articles were considered, published in English and Spanish, making use of the descriptors, a preliminary reading of the articles was carried out with the aim ofSelect those that fit our purpose, the documents that had information with the formal aspects, were included in our review, that is, a rigorous reading, which selected a total of 24 articles. It is at this point that clinical observation has made it possible to describe that not all patients have the same course of evolution of the disease, even with standardized treatments worldwide, and when evaluating the outcomes of the disease it is suggested that there must be characteristics of each patients who cause their disease to cause more damage in their evolution compared to other patients.

Palabras clave : rheumatoid arthritis; antirheumatic; biological products.

        · resumen en Español     · texto en Español     · Español ( pdf )